Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Christian Kellner; Stefanie Derer; Katja Klausz; Sophia Rosskopf; Tim Wirt; Thies Rösner; Anna Otte; Elisa Cappuzzello; Matthias Peipp

doi:10.1007/978-1-4939-8648-4_20

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Christian Kellner, Stefanie Derer, Katja Klausz, Sophia Rosskopf, Tim Wirt, Thies Rösner, Anna Otte, Elisa Cappuzzello, Matthias Peipp^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Medizinische Klinik I

Christian-Albrechts Universität zu Kiel

8 Zitate (Scopus)

Abstract

Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

Originalsprache	Englisch
Titel	Antibody Engineering
Redakteure/-innen	Damien Nevoltris, Patrick Chames
Seitenumfang	17
Band	1827
Erscheinungsort	New York, NY
Herausgeber (Verlag)	Humana Press Inc.
Erscheinungsdatum	09.09.2018
Seiten	381-397
ISBN (Print)	978-1-4939-8647-7
ISBN (elektronisch)	978-1-4939-8648-4
DOIs	https://doi.org/10.1007/978-1-4939-8648-4_20
Publikationsstatus	Veröffentlicht - 09.09.2018

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Dokumente

10.1007/978-1-4939-8648-4_20

Weitere Links

Link to publication in Scopus

Zitieren

Kellner, C., Derer, S., Klausz, K., Rosskopf, S., Wirt, T., Rösner, T., Otte, A., Cappuzzello, E., & Peipp, M. (2018). Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. in D. Nevoltris, & P. Chames (Hrsg.), Antibody Engineering (Band 1827, S. 381-397). (Methods in Molecular Biology; Band 1827). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8648-4_20

@inbook{ba220b4f281c4f0d81f8cf2eb5857b07,

title = "Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity",

abstract = "Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.",

author = "Christian Kellner and Stefanie Derer and Katja Klausz and Sophia Rosskopf and Tim Wirt and Thies R{\"o}sner and Anna Otte and Elisa Cappuzzello and Matthias Peipp",

year = "2018",

month = sep,

day = "9",

doi = "10.1007/978-1-4939-8648-4\_20",

language = "English",

isbn = "978-1-4939-8647-7",

volume = "1827",

series = "Methods in Molecular Biology",

publisher = "Humana Press Inc.",

pages = "381--397",

editor = "Nevoltris, \{Damien \} and Chames, \{Patrick \}",

booktitle = "Antibody Engineering",

}

Kellner, C, Derer, S, Klausz, K, Rosskopf, S, Wirt, T, Rösner, T, Otte, A, Cappuzzello, E & Peipp, M 2018, Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. in D Nevoltris & P Chames (Hrsg.), Antibody Engineering. Bd. 1827, Methods in Molecular Biology, Bd. 1827, Humana Press Inc., New York, NY, S. 381-397. https://doi.org/10.1007/978-1-4939-8648-4_20

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. / Kellner, Christian; Derer, Stefanie; Klausz, Katja et al.
Antibody Engineering. Hrsg. / Damien Nevoltris; Patrick Chames. Band 1827 New York, NY: Humana Press Inc., 2018. S. 381-397 (Methods in Molecular Biology; Band 1827).

Publikation: Kapitel in Büchern/Berichten/Konferenzbänden › Kapitel › Begutachtung

TY - CHAP

T1 - Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

AU - Kellner, Christian

AU - Derer, Stefanie

AU - Klausz, Katja

AU - Rosskopf, Sophia

AU - Wirt, Tim

AU - Rösner, Thies

AU - Otte, Anna

AU - Cappuzzello, Elisa

AU - Peipp, Matthias

PY - 2018/9/9

Y1 - 2018/9/9

N2 - Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

AB - Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

UR - https://www.scopus.com/pages/publications/85053074662

U2 - 10.1007/978-1-4939-8648-4_20

DO - 10.1007/978-1-4939-8648-4_20

M3 - Chapter

C2 - 30196508

AN - SCOPUS:85053074662

SN - 978-1-4939-8647-7

VL - 1827

T3 - Methods in Molecular Biology

SP - 381

EP - 397

BT - Antibody Engineering

A2 - Nevoltris, Damien

A2 - Chames, Patrick

PB - Humana Press Inc.

CY - New York, NY

ER -

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Abstract

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren